![](https://ml.globenewswire.com/media/a3b56d09-ded1-4678-b337-63884df06d1a/small/logo-01-3-copy-copy2-jpg.jpg)
ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-...
RENSSELAER, N.Y., July 24, 2024 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies for rare central nervous system (CNS) disorders, today announced that the U.S. Food and Drug …